Covid-19 roundup: Buoyed by soaring shares, Novavax inks a $167M deal to buy Covid-19 vaccine-making facility; France cools on hydroxychloroquine
The pandemic has offered the best news Novavax has had in years. Its stock price is trading at 7x the pre-panic levels with a Covid …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
